DiagnoCure gets DxS' Scorpions for colorectal cancer test:
This article was originally published in Clinica
Executive Summary
Manchester, UK-based molecular diagnostics company DxS has licensed its Scorpions technology to Canada's DiagnoCure for use in the latter's colorectal cancer tests. Financial terms of the agreement were not disclosed. DxS' technology is said to be ideal for cancer tests as it employs probes that are highly sensitive and specific, thereby improving productivity and lowering the costs of processing the tests. DiagnoCure will use the technology to detect GC-C (guanylyl cyclase c), a gene that appears normally in cells lining the intestinal tract, but is found on the outside of the intestine when colorectal cancer has metastasised.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.